Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986466 + Adagrasib +/- Cetuximab in Advanced KRAS G12C-mutant Solid Tumors
NCT06024174Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of BMS-986466 in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC) and 1 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Dose Limiting Toxicity, Number of Participants With Adverse Events up to 5 months and 2 more. Started Nov 2023; status: terminated.
02
Drugs
BMS-986466
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06024174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024174.